Designing conceptual model-based research in chemotherapy-related changes in cognitive function

Advances in Experimental Medicine and Biology

Volumn 678, Issue , 2010, Pages 37-54

  Hess, Lisa M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CHEMOTHERAPY; CANCER RESEARCH; CASE CONTROL STUDY; CLINICAL PROTOCOL; COGNITION; COHORT ANALYSIS; CONCEPTUAL FRAMEWORK; EVIDENCE BASED MEDICINE; EXPERIMENTAL DESIGN; HUMAN; INCIDENCE; METHODOLOGY; NOMENCLATURE; NON EXPERIMENTAL DESIGN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; CLINICAL TRIAL; DRUG THERAPY; MEDICAL RESEARCH; PHYSIOLOGY; THEORETICAL MODEL;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COGNITION; DRUG THERAPY; HUMANS; MODELS, THEORETICAL;

EID: 77956644627     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6306-2_8     Document Type: Review

References (37)

1. Anderson-Hanley C, Sherman ML, Riggs R et al. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 2003; 9(7):967-982. (Pubitemid 37428441)
2. Jansen CE, Miaskowski C, Dodd M et al. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 2005; 104(10):2222-2233. (Pubitemid 41579970)
3. Poster MI, Raichle ME. Images of Mind. New York: Freedman, 1994.
4. Matlin MW. Cognition. Crawfordsville: John Wiley and Sons 2003.
5. Craig FIM. Memory, aging and survey measurement. In: Schwarz N, Park D, Knauper B, Sudman S, ed. Cognition, Aging and Self-Reports. Ann Arbor: Psychology Press, 1999.
6. Budson AE. Understanding memory dysfunction. Neurologist 2009; 15(2):71-79.
7. Hurria A, Goldfarb S, Rosen C et al. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat 2006; 98(3):343-348. (Pubitemid 44195605)
8. Stewart A, Bielajew C, Collins B et al. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychologist 2006; 20(1):76-89.
9. Hess LM, Insel KC. Chemotherapy-related change in cognitive function: a conceptual model. Oncol Nurs Forum 2007; 34(5):981-994.
10. Vardy J, Wong K, Yi QL et al. Assessing cognitive function in cancer patients. Support Care Cancer 2006; 14(11):1111-1118 (Pubitemid 44898793)
11. Jansen CE, Miaskowski CA, Dodd MJ et al. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer. Oncol Nurs Forum 2007; 34(5):997-1005.
12. Schilder CM, Seynaeve C, Linn SC et al. The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy. Psycho-Oncology 2009.
13. Atkinson RC, Shiffrin RM. Human memory: A proposed system and its control processes. In: K.W. Spence JTS, ed. The Psychology of Learning and Motivation. New York: Academic Press, 1969.
14. Raaijmakers JGW. The story of the two-store model of memory: past criticisms, current status and future directions In: Kornblum DEMaS, ed. Attention and Performance XIV (Silver Jubilee Volume): Synergies in Experimental Psychology, Artificial intelligence and Cognitive Neuroscience. Cambridge: MIT Press, 1993.
15. Park DC. Cognitive aging, processing resources and self-report. In: Schwarz N, Park D, Knauper B, Sudman S, ed. Cognition, Aging and Self-Reports. Ann Arbor: Psychology Press, 1999.
16. Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst 2003; 95(3):190-197. (Pubitemid 36240631)
17. Meyers CA. Neurocognitive dysfunction in cancer patients. Oncology (Williston Park) 2000; 14(1):75-79; discussion 9, 81-2, 5.
18. Lenz ER, Pugh LC, Milligan RA et al. The middle-range theory of unpleasant symptoms: an update. Ans 1997; 19(3):14-27. (Pubitemid 127460653)
19. Barsevick AM, Whitmer K, Nail LM et al. Symptom cluster research: conceptual, design, measurement and analysis issues. J Pain Symp Manage 2006; 31(1):85-95. (Pubitemid 43143301)
20. Peterson SJ, Bredow TS. Middle Range Theories. Philadelphia: Lippincott Williams and Wilkins, 2004.
21. Fawcett J. Framework for analysis and evaluation of conceptual models of nursing. In: P.G. Reed NCS, L.H. Nicoll, ed. Perspectives on Nursing Theory. Philadelphia: Lippincott Williams and Wilkins 2004.
22. USPSTF. US Preventive Services Task Force Ratings: Grade Definitions. Guide to Clinical Preventive Services, Third Edition: Periodic Updates 2000-2003, Agency for Healthcare Research and Quality, Rockville, MD. [cited 2009]; Available from: http://www.ahrq.gov/clinic/3rduspstf/ratings.htm.
23. Phillips B, Ball C, Sackett D et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. 2009 [cited 2009]; Available from: http://www.cebm.net
24. Cunningham AJ, Phillips C, Lockwood GA et al. Association of involvement in psychological self-regulation with longer survival in patients with metastatic cancer: an exploratory study. Adv Mind-Body Med 2000; 16(4):276-287.
25. NCI. Cancer diagnosis program (CDP) of the National Cancer Institute. 2009 [cited 2009]; Available from: http://cancerdiagnosis.nci.nih.gov/funding/ clinical.htm
26. O'Neill BP, Wang CH, O'Fallon JR et al. The consequences of treatment and disease in patients with primary CNS nonHodgkin's lymphoma: cognitive function and performance status. North Central Cancer Treatment Group. Neuro-Oncology 1999; 1(3):196-203.
27. Kerlinger FN. Foundations of Behavioral Research. New York: Holt, Rinehard and Winston, Inc., 1973.
28. Correa DD, Ahles TA. Neurocognitive changes in cancer survivors. Cancer J (Sudbury, Mass) 2008; 14(6):396-400.
29. Young VM, Mazyck PJ, Schulz RM. Epidemiologic study designs. In: Simpson ECGCaKN, ed. Methods and Designs for Outcomes Research. Bethesda: American Society of Health-System Pharmacists, Inc., 2006.
30. Collins B, Mackenzie J, Stewart A et al. Cognitive effects of chemotherapy in postmenopausal breast cancer patients 1 year after treatment. Psycho-Oncology 2009; 18(2):134-143.
31. van Dam FS, Schagen SB, Muller MJ et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90(3):210-218. (Pubitemid 28114539)
32. Trochim WMK. The Research Methods Knowledge Base. Cincinnati: Cornell University Press 2001.
33. Campbell DT, Stanely JC. Experimental and Quasi-Experimental Designs for Research. Boston: Houghton Mifflin Company, 1963.
34. van Teijlingen ER, Hundley V. The importance of pilot studies. Social Research Update 2001; 35.
35. Hess LM, Chambers SK, Hatch K et al. Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer. J Supp Oncol, submitted 2009.
36. Alberts DS, Hess LM. Fundamentals of Cancer Prevention. Heidelberg: Springer-Verlag 2008.
37. Hensley ML, Correa DD, Thaler H et al. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecol Oncol 2006; 102(2):270-277. (Pubitemid 44063582)